Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort
- PMID: 21147030
- DOI: 10.1016/S1470-2045(10)70268-0
Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort
Abstract
Background: The increase in the worldwide incidence of endometrial cancer relates to rising obesity, falling fertility, and the ageing of the population. Transvaginal ultrasound (TVS) is a possible screening test, but there have been no large-scale studies. We report the performance of TVS screening in a large cohort.
Methods: We did a nested case-control study of postmenopausal women who underwent TVS in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) following recruitment between April 17, 2001, and Sept 29, 2005. Endometrial thickness and endometrial abnormalities were recorded, and follow-up, through national registries and a postal questionnaire, documented the diagnosis of endometrial cancer. Our primary outcome measure was endometrial cancer and atypical endometrial hyperplasia (AEH). Performance characteristics of endometrial thickness and abnormalities for detection of endometrial cancer within 1 year of TVS were calculated. Epidemiological variables were used to develop a logistic regression model and assess a screening strategy for women at higher risk. Our study is registered with ClinicalTrials.gov, number NCT00058032, and with the International Standard Randomised Controlled Trial register, number ISRCTN22488978.
Findings: 48,230 women underwent TVS in the UKCTOCS prevalence screen. 9078 women were ineligible because they had undergone a hysterectomy and 2271 because their endometrial thickness had not been recorded; however, 157 of these women had an endometrial abnormality on TVS and were included in the analysis. Median follow-up was 5·11 years (IQR 4·05-5·95). 136 women with endometrial cancer or AEH within 1 year of TVS were included in our primary analysis. The optimum endometrial thickness cutoff for endometrial cancer or AEH was 5·15 mm, with sensitivity of 80·5% (95% CI 72·7-86·8) and specificity of 86·2% (85·8-86·6). Sensitivity and specificity at a 5 mm or greater cutoff were 80·5% (72·7-86·8) and 85·7% (85·4-86·2); for women with a 5 mm or greater cutoff plus endometrial abnormalities, the sensitivity and specificity were 85·3% (78·2-90·8) and 80·4% (80·0-80·8), respectively. For a cutoff of 10 mm or greater, sensitivity and specificity were 54·1% (45·3-62·8) and 97·2% (97·0-97·4). When our analysis was restricted to the 96 women with endometrial cancer or AEH who reported no symptoms of postmenopausal bleeding at the UKCTOCS scan before diagnosis and had an endometrial thickness measurement available, a cutoff of 5 mm achieved a sensitivity of 77·1% (67·8-84·3) and specificity of 85·8% (85·7-85·9). The logistic regression model identified 25% of the population as at high risk and 39·5% of endometrial cancer or AEH cases were identified within this high risk group. In this high-risk population, a cutoff at 6·75 mm achieved sensitivity of 84·3% (71·4-93·0) and specificity of 89·9% (89·3-90·5).
Interpretation: Our findings show that TVS screening for endometrial cancer has good sensitivity in postmenopausal women. The burden of diagnostic procedures and false-positive results can be reduced by limiting screening to a higher-risk group. The role of population screening for endometrial cancer remains uncertain, but our findings are of immediate value in the management of increased endometrial thickness in postmenopausal women undergoing pelvic scans for reasons other than vaginal bleeding.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Comment in
-
Should we screen for endometrial cancer?Lancet Oncol. 2011 Jan;12(1):4-5. doi: 10.1016/S1470-2045(10)70280-1. Epub 2010 Dec 10. Lancet Oncol. 2011. PMID: 21147031 No abstract available.
Similar articles
-
Serial endometrial thickness and risk of non-endometrial hormone-dependent cancers in postmenopausal women in UK Collaborative Trial of Ovarian Cancer Screening.Ultrasound Obstet Gynecol. 2020 Aug;56(2):267-275. doi: 10.1002/uog.21894. Ultrasound Obstet Gynecol. 2020. PMID: 31614036 Free PMC article.
-
Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial.Health Technol Assess. 2025 May;29(10):1-93. doi: 10.3310/BHBR5832. Health Technol Assess. 2025. PMID: 37183782 Free PMC article. Clinical Trial.
-
Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).Lancet Oncol. 2009 Apr;10(4):327-40. doi: 10.1016/S1470-2045(09)70026-9. Epub 2009 Mar 11. Lancet Oncol. 2009. PMID: 19282241 Clinical Trial.
-
Risk of endometrial cancer in asymptomatic postmenopausal women in relation to ultrasonographic endometrial thickness: systematic review and diagnostic test accuracy meta-analysis.Am J Obstet Gynecol. 2023 Jan;228(1):22-35.e2. doi: 10.1016/j.ajog.2022.07.043. Epub 2022 Aug 4. Am J Obstet Gynecol. 2023. PMID: 35932873
-
Two-dimensional transvaginal sonography vs saline contrast sonohysterography for diagnosing endometrial polyps: systematic review and meta-analysis.Ultrasound Obstet Gynecol. 2020 Oct;56(4):506-515. doi: 10.1002/uog.22161. Epub 2020 Sep 14. Ultrasound Obstet Gynecol. 2020. PMID: 32730635
Cited by
-
Endometrial Polyps - When Should Hysteroscopic Resection Be Performed?Rev Bras Ginecol Obstet. 2016 Jul;38(7):315-6. doi: 10.1055/s-0036-1586488. Epub 2016 Jul 29. Rev Bras Ginecol Obstet. 2016. PMID: 27472809 Free PMC article. No abstract available.
-
Screening Strategies to Improve Early Diagnosis in Endometrial Cancer.J Clin Med. 2024 Sep 13;13(18):5445. doi: 10.3390/jcm13185445. J Clin Med. 2024. PMID: 39336931 Free PMC article. Review.
-
Combined genetic mutations and DNA-methylated genes as biomarkers for endometrial cancer detection from cervical scrapings.Clin Epigenetics. 2019 Nov 28;11(1):170. doi: 10.1186/s13148-019-0765-3. Clin Epigenetics. 2019. PMID: 31779688 Free PMC article.
-
Contrast-enhanced ultrasound in the diagnosis of endometrial carcinoma: A meta-analysis.Exp Ther Med. 2018 Dec;16(6):5310-5314. doi: 10.3892/etm.2018.6889. Epub 2018 Oct 22. Exp Ther Med. 2018. PMID: 30542488 Free PMC article.
-
The value of MRI in management of endometrial hyperplasia with atypia.World J Surg Oncol. 2020 Feb 10;18(1):34. doi: 10.1186/s12957-020-1811-5. World J Surg Oncol. 2020. PMID: 32041614 Free PMC article.
Publication types
MeSH terms
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous